论文部分内容阅读
目的比较紫杉醇联合顺铂(TP方案)和诺维本联合顺铂(NP方案)治疗晚期复发性非小细胞肺癌的疗效及毒性反应。方法选择复发性NSCLC患者,随机分为两组,分别用TP方案、NP方案治疗。结果两组患者中TP方案有效率43.3%,中位生存期8.5个月,毒副反应主要为骨髓抑制、消化道反应;NP方案有效率36.7%,中位生存期7.5个月,两组毒性能耐受,本组无因治疗引起的死亡。结论紫杉醇联合顺铂(TP方案)和诺维本联合顺铂(NP方案)治疗晚期复发性非小细胞肺癌有效,两组疗效相似。
Objective To compare the efficacy and toxicity of paclitaxel combined with cisplatin (TP) and nobiletin combined with cisplatin (NP) in the treatment of advanced recurrent non-small cell lung cancer. Methods Patients with recurrent NSCLC were randomly divided into two groups and treated with TP regimen and NP regimen respectively. Results The effective rate of TP was 43.3% in both groups and the median survival time was 8.5 months. The main side effects were myelosuppression and digestive tract reaction. The effective rate of NP regimen was 36.7% and the median survival time was 7.5 months. Performance tolerance, no death caused by treatment in this group. Conclusions Paclitaxel combined with cisplatin (TP regimen) and noviben combined with cisplatin (NP regimen) are effective in treating patients with advanced recurrent non-small cell lung cancer with similar efficacy.